John Wiley & Sons has bounced back from last week's sharp reversal, but the options market isn't yet buying the recovery.
The stock closed Tuesday at $50.76, up 3% on the week and 8.7% over the past month. That recovery meaningfully reverses the 5.8% weekly drop flagged in last week's note. The momentum is real — WLY is trading near its 52-week high, and the stock's ORTEX short score has held broadly stable in the mid-60s through this period.
The options story, however, has taken a more cautious turn. Put demand has spiked sharply again relative to calls. The put/call ratio jumped to 0.37 on Tuesday — more than double its 20-day average of 0.16, and 3.4 standard deviations above that mean. That's an unusually large one-day shift, especially after the PCR had retreated to its floor of 0.12 on Monday. For context, the 20-day average itself is low: WLY options have been dominated by call flow for much of this month, making Tuesday's put surge stand out all the more. The pattern echoes the defensive spike seen on June 30, when the PCR briefly climbed to 0.30, before quickly reverting. Whether Tuesday's move is a hedge ahead of the September 3 earnings date or a response to some other positioning need is unclear, but the abruptness is notable.
Short interest and borrow conditions remain orderly, consistent with what was described last week. Short positions have eased marginally — down about 0.9% on the week to roughly 4.1 million shares. Borrow availability is running at approximately 349% of short interest, well above last year's tightest level near 265%, and cost to borrow sits at just 0.51%. There is no squeeze pressure here. The short score of 64.9 ranks in the 7th percentile for short squeeze potential, reflecting a setup where bears are present but the lending market gives them plenty of room.
The institutional picture shows broad, stable ownership. BlackRock and State Street both added modestly in the most recent quarter. A notable seller is Peter Wiley, whose position declined by over 700,000 shares to 1.2 million — a family-name holder trimming a large legacy stake. On the insider side, the June 30 activity was routine: equity awards to senior executives accompanied by small sell-to-cover transactions. The CEO received a share award but no open-market purchase, offering no directional read on management conviction.
The mean analyst price target of $68 implies roughly 34% upside to the current price, though all available analyst actions in the data are years old and should not be treated as current Street positioning. The EPS surprise factor score of 79 out of 100 indicates the company has a strong track record of beating estimates — a useful reference point with the next earnings event now six weeks away on September 3.
What to watch: whether the Tuesday put spike persists into the rest of the week or reverts quickly, as it did on June 30, will clarify whether defensive positioning is building ahead of the September earnings date or simply reflects a one-session hedge in a thinly traded options book.
See the live data behind this article on ORTEX.
Open WLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
